Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension (Q37944298)

25 August 2017

title

Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension (English)

1 reference

25 August 2017

main subject

arterial hypertension

0 references

1 reference

Matthew Ferrantino

1

1 reference

25 August 2017

R James White

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

volume

12

1 reference

25 August 2017

issue

16

1 reference

25 August 2017

page(s)

2583-2593

1 reference

Updated clinical classification of pulmonary hypertension.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Pulmonary arterial hypertension in France: results from a national registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Cellular and molecular pathobiology of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Prostacyclin and its analogues in the treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Inhaled prostanoids in the therapy of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Prostacyclin (PGI2) synthase is a constitutively expressed enzyme in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Pharmacodynamic profile of prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Prostanoid therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.622269

10.1517/14656566.2011.622269

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference